Relation of Serum Soluble Suppression of Tumorigenicity 2 with Cardiovascular Complications in Chronic Kidney Disease Patients

Chronic kidney disease (CKD) is defined as a reduced glomerular filtration rate, increased urinary albumin excretion, or both, and is an increasing public health issue. Prevalence is estimated to be 8–16% worldwide. The aim is to study the correlation between the level of soluble Suppression of Tumorigenicity 2 (sST2) in patients with chronic kidney disease and cardiovascular (CV) complications in these patients. This study was carried out on 89 patients having CKD aged above 18 years, of both sexes. Patients were collected from Al-Zahraa University Hospital Internal Medicine Department in the period from January 2021 to June 2021. They were divided into: Group One (30 CKD patients) having cardiovascular complications, and Group Two (59 CKD patients) without cardiovascular complications. Their analyses were done at Al Zahraa University Hospital, Clinical Pathology Department. The present study showed that Serum sST2 was significantly increased in CKD patients with cardiovascular complications represented by decreased LVEF%. Also, this biomarker is independent of eGFR, age, sex, creatinine, BUN, uric acid, HbA1C, cholesterol, triglycerides, LDL, and HDL. The present study proved that sST2 is a promising new biomarker to detect cardiac affection in chronic kidney disease patients and this biomarker is independent of eGFR and age.